RankingsPricing
  1. US-listed companies
  2. REGENERON PHARMACEUTICALS, INC.
  3. Financials
  4. Operating expenses

REGENERON PHARMACEUTICALS, INC.REGN

Market cap
$85B
P/E ratio
SummaryFinancials
Period EndOperating expenses (Million USD)YoY (%)
Dec 31, 202410,211+12.58%
Dec 31, 20239,070+22.01%
Dec 31, 20227,434+4.34%
Dec 31, 20217,125+44.80%
Dec 31, 20204,921-12.97%
Dec 31, 20195,654+35.37%
Dec 31, 20184,176+10.12%
Dec 31, 20173,793+7.45%
Dec 31, 20163,530+23.77%
Dec 31, 20152,852+43.95%
Dec 31, 20141,981+47.33%
Dec 31, 20131,345+46.04%
Dec 31, 2012921+41.44%
Dec 31, 2011651+16.97%
Dec 31, 2010557

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)